The DOI matches its Crossref record; 182 of the 182 references it cites were found in a registry or an index.
Antitumour actions of interferons: implications for cancer therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Interferon-γ: an overview of signals, mechanisms and functions
Schroder, K., Hertzog, P. J., Ravasi, T., & Hume, D. A. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0603252 · Cited by 4,120
Self-citationMechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1604 · Cited by 3,491
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
CELLULAR RESPONSES TO INTERFERON-γ
Boehm, U., Klamp, T., Groot, M., & Howard, J. C. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.749 · Cited by 2,890
Lanier, L. L. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115526 · Cited by 2,769
Innate lymphoid cells — a proposal for uniform nomenclature
Spits, H., Artis, D., Colonna, M., Diefenbach, A., Di Santo, J. P., Eberl, G., Koyasu, S., Locksley, R. M., McKenzie, A. N. J., Mebius, R. E., et al. (2013) · Nature Reviews Immunology · doi:10.1038/nri3365 · Cited by 2,389
Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy
Fulda, S., & Debatin, K.-M. (2006) · Oncogene · doi:10.1038/sj.onc.1209608 · Cited by 2,312
NATURAL KILLER CELLS IN ANTIVIRAL DEFENSE: Function and Regulation by Innate Cytokines
Biron, C. A., Nguyen, K. B., Pien, G. C., Cousens, L. P., & Salazar-Mather, T. P. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.189 · Cited by 2,113
An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis
Berry, M. P. R., Graham, C. M., McNab, F. W., Xu, Z., Bloch, S. A. A., Oni, T., Wilkinson, K. A., Banchereau, R., Skinner, J., Wilkinson, R. J., et al. (2010) · Nature · doi:10.1038/nature09247 · Cited by 1,898
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex
Kotenko, S. V., Gallagher, G., Baurin, V. V., Lewis-Antes, A., Shen, M., Shah, N. K., Langer, J. A., Sheikh, F., Dickensheets, H., & Donnelly, R. P. (2003) · Nature Immunology · doi:10.1038/ni875 · Cited by 1,868
Cross-presentation by dendritic cells
Joffre, O. P., Segura, E., Savina, A., & Amigorena, S. (2012) · Nature Reviews Immunology · doi:10.1038/nri3254 · Cited by 1,637
IPC: Professional Type 1 Interferon-Producing Cells and Plasmacytoid Dendritic Cell Precursors
Liu, Y.-J. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115633 · Cited by 1,625
Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465
A Pooled Analysis of Bone Marrow Micrometastasis in Breast Cancer
Braun, S., Vogl, F. D., Naume, B., Janni, W., Osborne, M. P., Coombes, R. C., Schlimok, G., Diel, I. J., Gerber, B., Gebauer, G., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050434 · Cited by 1,379
Potent and Selective Stimulation of Memory-Phenotype CD8+ T Cells In Vivo by IL-15
Zhang, X., Sun, S., Hwang, I., Tough, D. F., & Sprent, J. (1998) · Immunity · doi:10.1016/s1074-7613(00)80564-6 · Cited by 1,245
Fuertes, M. B., Kacha, A. K., Kline, J., Woo, S.-R., Kranz, D. M., Murphy, K. M., & Gajewski, T. F. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101159 · Cited by 1,192
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042
The Impact of PEGylation on Biological Therapies
Veronese, F. M., & Mero, A. (2008) · BioDrugs · doi:10.2165/00063030-200822050-00004 · Cited by 1,034
Systemic effects of local radiotherapy
Formenti, S. C., & Demaria, S. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70082-8 · Cited by 1,021
Seder, R. A., Gazzinelli, R., Sher, A., & Paul, W. E. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.21.10188 · Cited by 976
Kirkwood, J. M., Ibrahim, J. G., Sosman, J. A., Sondak, V. K., Agarwala, S. S., Ernstoff, M. S., & Rao, U. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2370 · Cited by 898
Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 870
Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis
Chawla-Sarkar, M., Lindner, D. J., Liu, Y.-F., Williams, B. R., Sen, G. C., Silverman, R. H., & Borden, E. C. (2003) · Apoptosis · doi:10.1023/a:1023668705040 · Cited by 829
Cancer--A Biological Approach: I. The Processes Of Control. II. The Significance of Somatic Mutation
Burnet, M. (1957) · BMJ · doi:10.1136/bmj.1.5022.779 · Cited by 810
Type I Interferons Keep Activated T Cells Alive
Marrack, P., Kappler, J., & Mitchell, T. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.3.521 · Cited by 759
De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent
de Visser, K. E., Korets, L. V., & Coussens, L. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.014 · Cited by 715
Olkhanud, P. B., Damdinsuren, B., Bodogai, M., Gress, R. E., Sen, R., Wejksza, K., Malchinkhuu, E., Wersto, R. P., & Biragyn, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4316 · Cited by 684
Fehniger, T. A., Shah, M. H., Turner, M. J., VanDeusen, J. B., Whitman, S. P., Cooper, M. A., Suzuki, K., Wechser, M., Goodsaid, F., & Caligiuri, M. A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.8.4511 · Cited by 652
Eggermont, A. M., Suciu, S., Santinami, M., Testori, A., Kruit, W. H., Marsden, J., Punt, C. J., Salès, F., Gore, M., MacKie, R., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61033-8 · Cited by 640
Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients
Rack, B., Schindlbeck, C., Jückstock, J., Andergassen, U., Hepp, P., Zwingers, T., Friedl, T. W. P., Lorenz, R., Tesch, H., Fasching, P. A., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju066 · Cited by 615
Inflammatory cytokines as a third signal for T cell activation
Curtsinger, J. M., & Mescher, M. F. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.02.013 · Cited by 615
Nguyen, K. B., Salazar-Mather, T. P., Dalod, M. Y., Van Deusen, J. B., Wei, X.-Q., Liew, F. Y., Caligiuri, M. A., Durbin, J. E., & Biron, C. A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.8.4279 · Cited by 610
A critical function for type I interferons in cancer immunoediting
Dunn, G. P., Bruce, A. T., Sheehan, K. C. F., Shankaran, V., Uppaluri, R., Bui, J. D., Diamond, M. S., Koebel, C. M., Arthur, C., White, J. M., et al. (2005) · Nature Immunology · doi:10.1038/ni1213 · Cited by 605
Nielsen, J. S., Sahota, R. A., Milne, K., Kost, S. E., Nesslinger, N. J., Watson, P. H., & Nelson, B. H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0234 · Cited by 553
Mocellin, S., Pasquali, S., Rossi, C. R., & Nitti, D. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq009 · Cited by 527
Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells.
Brinkmann, V, Geiger, T., Alkan, S., & Heusser, C. H. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.5.1655 · Cited by 506
Direct Effects of Type I Interferons on Cells of the Immune System
Hervas-Stubbs, S., Perez-Gracia, J. L., Rouzaut, A., Sanmamed, M. F., Le Bon, A., & Melero, I. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1114 · Cited by 503
GUTTERMAN, J. U., BLUMENSCHEIN, G. R., ALEXANIAN, R., YAP, H.-Y., BUZDAR, A. U., CABANILLAS, F., HORTOBAGYI, G. N., HERSH, E. M., RASMUSSEN, S. L., HARMON, M., et al. (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-3-399 · Cited by 497
Stagg, J., Loi, S., Divisekera, U., Ngiow, S. F., Duret, H., Yagita, H., Teng, M. W., & Smyth, M. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016569108 · Cited by 496
Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape
Bidwell, B. N., Slaney, C. Y., Withana, N. P., Forster, S., Cao, Y., Loi, S., Andrews, D., Mikeska, T., Mangan, N. E., Samarajiwa, S. A., et al. (2012) · Nature Medicine · doi:10.1038/nm.2830 · Cited by 487
Self-citationConstitutive Type I Interferon Modulates Homeostatic Balance through Tonic Signaling
Gough, D. J., Messina, N. L., Clarke, C. J. P., Johnstone, R. W., & Levy, D. E. (2012) · Immunity · doi:10.1016/j.immuni.2012.01.011 · Cited by 470
Dendritic Cell Infiltration and Prognosis of Early Stage Breast Cancer
Treilleux, I., Blay, J.-Y., Bendriss-Vermare, N., Ray-Coquard, I., Bachelot, T., Guastalla, J.-P., Bremond, A., Goddard, S., Pin, J.-J., Barthelemy-Dubois, C., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0684 · Cited by 460
Mattei, F., Schiavoni, G., Belardelli, F., & Tough, D. F. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.3.1179 · Cited by 459
Bromberg, J. F., Horvath, C. M., Wen, Z., Schreiber, R. D., & Darnell, J. E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7673 · Cited by 422
Chiche, L., Jourde‐Chiche, N., Whalen, E., Presnell, S., Gersuk, V., Dang, K., Anguiano, E., Quinn, C., Burtey, S., Berland, Y., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38628 · Cited by 420
Interferon-Lambda: A New Addition to an Old Family
Donnelly, R. P., & Kotenko, S. V. (2010) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2010.0078 · Cited by 420
Burkett, P. R., Koka, R., Chien, M., Chai, S., Boone, D. L., & Ma, A. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041389 · Cited by 392
Hwang, S. Y., Hertzog, P. J., Holland, K. A., Sumarsono, S. H., Tymms, M. J., Hamilton, J. A., Whitty, G., Bertoncello, I., & Kola, I. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.24.11284 · Cited by 377
Self-citationInterferon-induced nuclear signalling by Jak protein tyrosine kinases
Silvennoinen, O., Ihle, J. N., Schlessinger, J., & Levy, D. E. (1993) · Nature · doi:10.1038/366583a0 · Cited by 376
Schiavoni, G., Sistigu, A., Valentini, M., Mattei, F., Sestili, P., Spadaro, F., Sanchez, M., Lorenzi, S., D'Urso, M. T., Belardelli, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2788 · Cited by 362
Le Bon, A., Thompson, C., Kamphuis, E., Durand, V., Rossmann, C., Kalinke, U., & Tough, D. F. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.4.2074 · Cited by 361
RapV12 antagonizes Ras-dependent activation of ERK1 and ERK2 by LPA and EGF in Rat-1 fibroblasts.
Cook, S. J., Rubinfeld, B., Albert, I., & McCormick, F. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb06022.x · Cited by 349
Sisirak, V., Faget, J., Gobert, M., Goutagny, N., Vey, N., Treilleux, I., Renaudineau, S., Poyet, G., Labidi-Galy, S. I., Goddard-Leon, S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3468 · Cited by 345
Immunological Surveillance in Neoplasia
Burnet, F. M. (1971) · Immunological Reviews · doi:10.1111/j.1600-065x.1971.tb00461.x · Cited by 342
Type I IFN Contributes to NK Cell Homeostasis, Activation, and Antitumor Function
Swann, J. B., Hayakawa, Y., Zerafa, N., Sheehan, K. C. F., Scott, B., Schreiber, R. D., Hertzog, P., & Smyth, M. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.12.7540 · Cited by 339
Self-citationPivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors
Mattarollo, S. R., Loi, S., Duret, H., Ma, Y., Zitvogel, L., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0753 · Cited by 333
Duluc, D., Corvaisier, M., Blanchard, S., Catala, L., Descamps, P., Gamelin, E., Ponsoda, S., Delneste, Y., Hebbar, M., & Jeannin, P. (2009) · International Journal of Cancer · doi:10.1002/ijc.24401 · Cited by 329
Liu, C., Lou, Y., Lizée, G., Qin, H., Liu, S., Rabinovich, B., Kim, G. J., Wang, Y.-H., Ye, Y., Sikora, A. G., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33583 · Cited by 316
Mechanism of the Antitumour Effect of Interferon in Mice
GRESSER, I., MAURY, C., & BROUTY-BOYÉ, D. (1972) · Nature · doi:10.1038/239167a0 · Cited by 313
Interferon-κ, a Novel Type I Interferon Expressed in Human Keratinocytes
LaFleur, D. W., Nardelli, B., Tsareva, T., Mather, D., Feng, P., Semenuk, M., Taylor, K., Buergin, M., Chinchilla, D., Roshke, V., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102502200 · Cited by 288
Eggermont, A. M. M., Suciu, S., Testori, A., Santinami, M., Kruit, W. H. J., Marsden, J., Punt, C. J. A., Salès, F., Dummer, R., Robert, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.3799 · Cited by 285
Schreiner, B., Mitsdoerffer, M., Kieseier, B. C., Chen, L., Hartung, H.-P., Weller, M., & Wiendl, H. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.06.013 · Cited by 275
Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells
Eppihimer, M., Gunn, J., Freeman, G., Greenfield, E., Chernova, T., Erickson, J., & Leonard, J. (2002) · Microcirculation · doi:10.1080/713774061 · Cited by 272
IFN‐α/β enhances BCR‐dependent B cell responses
Braun, D., Caramalho, I., & Demengeot, J. (2002) · International Immunology · doi:10.1093/intimm/14.4.411 · Cited by 268
INTERFEROME: the database of interferon regulated genes
Samarajiwa, S. A., Forster, S., Auchettl, K., & Hertzog, P. J. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn732 · Cited by 265
Self-citationStructural basis of a unique interferon-β signaling axis mediated via the receptor IFNAR1
de Weerd, N. A., Vivian, J. P., Nguyen, T. K., Mangan, N. E., Gould, J. A., Braniff, S.-J., Zaker-Tabrizi, L., Fung, K. Y., Forster, S. C., Beddoe, T., et al. (2013) · Nature Immunology · doi:10.1038/ni.2667 · Cited by 264
Self-citationInterferon-ε Protects the Female Reproductive Tract from Viral and Bacterial Infection
Fung, K. Y., Mangan, N. E., Cumming, H., Horvat, J. C., Mayall, J. R., Stifter, S. A., De Weerd, N., Roisman, L. C., Rossjohn, J., Robertson, S. A., et al. (2013) · Science · doi:10.1126/science.1233321 · Cited by 261
Self-citationInterferons and Their Stimulated Genes in the Tumor Microenvironment
Cheon, H., Borden, E. C., & Stark, G. R. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.02.002 · Cited by 255
Lutfalla, G., Holland, S. J., Cinato, E., Monneron, D., Reboul, J., Rogers, N. C., Smith, J. M., Stark, G. R., Gardiner, K., & Mogensen, K. E. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00192.x · Cited by 248
Mechanisms of Interferon-alpha induced apoptosis in malignant cells
Thyrell, L., Erickson, S., Zhivotovsky, B., Pokrovskaja, K., Sangfelt, O., Castro, J., Einhorn, S., & Grandér, D. (2002) · Oncogene · doi:10.1038/sj.onc.1205179 · Cited by 239
Waldmann, T. A. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0009 · Cited by 238
CpG Blocks Immunosuppression by Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Zoglmeier, C., Bauer, H., Nörenberg, D., Wedekind, G., Bittner, P., Sandholzer, N., Rapp, M., Anz, D., Endres, S., & Bourquin, C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2672 · Cited by 238
Wong, L. H., Krauer, K. G., Hatzinisiriou, I., Estcourt, M. J., Hersey, P., Tam, N. D., Edmondson, S., Devenish, R. J., & Ralph, S. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.45.28779 · Cited by 234
Greiner, J. W., Hand, P. H., Noguchi, P. D., Fisher, P. B., Pestka, S., & Schlom, J. (1984) · PubMed · Cited by 221
Inverse Interference: How Viruses Fight the Interferon System
Weber, F., Kochs, G., & Haller, O. (2004) · Viral Immunology · doi:10.1089/vim.2004.17.498 · Cited by 217
Cancer immunotherapy: The interferon-α experience
Kirkwood, J. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.33078 · Cited by 213
Dynamic control of type I IFN signalling by an integrated network of negative regulators
Porritt, R. A., & Hertzog, P. J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.002 · Cited by 196
Self-citationThe molecular basis for functional plasticity in type I interferon signaling
Schreiber, G., & Piehler, J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.01.002 · Cited by 193
Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells
Sathe, P., Delconte, R. B., Souza-Fonseca-Guimaraes, F., Seillet, C., Chopin, M., Vandenberg, C. J., Rankin, L. C., Mielke, L. A., Vikstrom, I., Kolesnik, T. B., et al. (2014) · Nature Communications · doi:10.1038/ncomms5539 · Cited by 187
Borden, E. C., Hogan, T. F., & Voelkel, J. G. (1982) · PubMed · Cited by 186
Sun, W. H., Pabon, C., Alsayed, Y., Huang, P. P., Jandeska, S., Uddin, S., Platanias, L. C., & Rosen, S. T. (1998) · Blood · doi:10.1182/blood.v91.2.570 · Cited by 169
Type I Interferons as Stimulators of DC-Mediated Cross-Priming: Impact on Anti-Tumor Response
Schiavoni, G., Mattei, F., & Gabriele, L. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00483 · Cited by 169
Piontek, G. E., Taniguchi, K., Ljunggren, H. G., Grönberg, A., Kiessling, R., Klein, G., & Kärre, K. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.6.4281 · Cited by 168
Type I IFN enhances follicular B cell contribution to the T cell–independent antibody response
Swanson, C. L., Wilson, T. J., Strauch, P., Colonna, M., Pelanda, R., & Torres, R. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092695 · Cited by 166
Srivastava, S., Koch, M. A., Pepper, M., & Campbell, D. J. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131556 · Cited by 162
A Multiple-Dose Phase I Trial of Recombinant Leukocyte A Interferon in Cancer Patients
Sherwin, S. A., Knost, J. A., Fein, S., Abrams, P. G., Foon, K. A., Ochs, J. J., Schoenberger, C., Maluish, A. E., & Oldham, R. K. (1982) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1982.03330190025025 · Cited by 161
Immune modulation for cancer therapy
Naidoo, J., Page, D. B., & Wolchok, J. D. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.348 · Cited by 150
Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells.
Eppihimer, M. J., Gunn, J., Freeman, G. J., Greenfield, E. A., Chernova, T., Erickson, J., & Leonard, J. P. (2002) · PubMed · doi:10.1038/sj/mn/7800123 · Cited by 149
Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
Talpaz, M., Hehlmann, R., Quintás‐Cardama, A., Mercer, J., & Cortes, J. E. (2012) · Leukemia · doi:10.1038/leu.2012.313 · Cited by 148
Yamaguchi, R., Tanaka, M., Yano, A., Tse, G. M.-K., Yamaguchi, M., Koura, K., Kanomata, N., Kawaguchi, A., Akiba, J., Naito, Y., et al. (2012) · Human Pathology · doi:10.1016/j.humpath.2011.12.013 · Cited by 147
Systems Biology of Interferon Responses
Hertzog, P. J., Forster, S. C., & Samarajiwa, S. (2011) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2010.0126 · Cited by 144
Self-citationCheon, H., Yang, J. B., & Stark, G. R. (2010) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2010.0100 · Cited by 144
TLR3 as a Biomarker for the Therapeutic Efficacy of Double-stranded RNA in Breast Cancer
Salaun, B., Zitvogel, L., Asselin‐Paturel, C., Morel, Y., Chemin, K., Dubois, C., Massacrier, C., Conforti, R., Chenard, M. P., Sabourin, J., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3490 · Cited by 130
Regulatory T cells and breast cancer: implications for immunopathogenesis
Watanabe, M. A. E., Oda, J. M. M., Amarante, M. K., & Voltarelli, J. C. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9247-y · Cited by 125
Fine tuning type I interferon responses
Hertzog, P. J., & Williams, B. R. G. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.04.002 · Cited by 125
Self-citationGiuliano, M., Giordano, A., Jackson, S. A., Giorgi, U. D., Mego, M., Cohen, E. N., Gao, H., Anfossi, S., Handy, B. C., Ueno, N. T., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0440-8 · Cited by 124
Interferon Induces Natural Killer Cell Blastogenesis In Vivo
Biron, C. A., Sonnenfeld, G., & Welsh, R. M. (1984) · Journal of Leukocyte Biology · doi:10.1002/jlb.35.1.31 · Cited by 118
Lapatinib and doxorubicin enhance the S tat1‐dependent antitumor immune response
Hannesdóttir, L., Tymoszuk, P., Parajuli, N., Wasmer, M.-H., Philipp, S., Daschil, N., Datta, S., Koller, J., Tripp, C. H., Stoitzner, P., et al. (2013) · European Journal of Immunology · doi:10.1002/eji.201242505 · Cited by 115
Interferon-signaling pathway: associations with colon and rectal cancer risk and subsequent survival
Slattery, M. L., Lundgreen, A., Bondurant, K. L., & Wolff, R. K. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr189 · Cited by 115
Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma.
PROPPER, D. J., Chao, D., Braybrooke, J. P., Bahl, P., Thavasu, P., Balkwill, F. R., Turley, H., Dobbs, N. A., Gatter, K. C., Talbot, D. C., et al. (2003) · PubMed · Cited by 115
The tumor suppressor function of STAT1 in breast cancer
Koromilas, A. E., & Sexl, V. (2013) · JAK-STAT · doi:10.4161/jkst.23353 · Cited by 112
Interferon-α Suppresses cAMP to Disarm Human Regulatory T Cells
Bacher, N., Raker, V., Hofmann, C., Graulich, E., Schwenk, M., Baumgrass, R., Bopp, T., Zechner, U., Merten, L., Becker, C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3788 · Cited by 111
Hardy, M. P., Owczarek, C. M., Trajanovska, S., Liu, X., Kola, I., & Hertzog, P. J. (2001) · Blood · doi:10.1182/blood.v97.2.473 · Cited by 110
Self-citationWidschwendter, A., Geymayer, S., Welte, T., Daxenbichler, G., Marth, C., & Doppler, W. (2002) · PubMed · Cited by 108
Yadav, D., Ngolab, J., Lim, R. S.-H., Krishnamurthy, S. R., & Bui, J. D. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.1.39 · Cited by 108
Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice
Levy, D. E., & Gilliland, D. G. (2000) · Oncogene · doi:10.1038/sj.onc.1203480 · Cited by 108
Hobeika, A. C., Subramaniam, P. S., & Johnson, H. M. (1997) · Oncogene · doi:10.1038/sj.onc.1200939 · Cited by 107
Stochastic Receptor Expression Determines Cell Fate upon Interferon Treatment
Levin, D., Harari, D., & Schreiber, G. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05251-11 · Cited by 105
IFN-Dependent Down-Regulation of the NKG2D Ligand H60 on Tumors
Bui, J. D., Carayannopoulos, L. N., Lanier, L. L., Yokoyama, W. M., & Schreiber, R. D. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.2.905 · Cited by 104
Quesada, J. R., Hawkins, M., Horning, S. J., Alexanian, R., Borden, E. C., Merigan, T. C., Adams, F., & Gutterman, J. U. (1984) · The American Journal of Medicine · doi:10.1016/0002-9343(84)90097-4 · Cited by 100
Inhibition by lymphoblastoid interferon of growth of cells derived from the human breast
Balkwill, F. R., Watling, D., & Taylor‐Papadimitriou, J. (1978) · International Journal of Cancer · doi:10.1002/ijc.2910220307 · Cited by 100
Demaria, S., Pilones, K. A., Vanpouille‐Box, C., Golden, E. B., & Formenti, S. C. (2014) · Radiation Research · doi:10.1667/rr13500.1 · Cited by 95
Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors.
Gresser, I., Belardelli, F., Maury, C., Maunoury, M. T., & Tovey, M. G. (1983) · The Journal of Experimental Medicine · doi:10.1084/jem.158.6.2095 · Cited by 93
APC Activation by IFN-α Decreases Regulatory T Cell and Enhances Th Cell Functions
Pace, L., Vitale, S., Dettori, B., Palombi, C., Sorsa, V. L., Belardelli, F., Proietti, E., & Doria, G. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0900526 · Cited by 91
Lü, M., Zhang, W., Li, Y., Berenzon, D. P., Wang, X., Wang, J., Mascarenhas, J. O., Xu, M., & Hoffman, R. (2010) · Experimental Hematology · doi:10.1016/j.exphem.2010.03.005 · Cited by 88
Łuszczek, W., Cheriyath, V., Mekhail, T. M., & Borden, E. C. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0309 · Cited by 87
Yang, I., Kremen, T. J., Giovannone, A. J., Paik, E., Odesa, S. K., Prins, R. M., & Liau, L. M. (2004) · Journal of neurosurgery · doi:10.3171/jns.2004.100.2.0310 · Cited by 86
ADJUVANT TREATMENT WITH POLYADENYLIC-POLYURIDYLIC ACID (POLYA.POLYU) IN OPERABLE BREAST CANCER
Lacour, J., Spira, A., Petit, J., Sarrazin, D., Lacour, F., Michelson, M., Delage, G. L., Contesso, G., & Viguier, J. (1980) · The Lancet · doi:10.1016/s0140-6736(80)90057-4 · Cited by 86
van den Berg, H., Leahey, W., Lynch, M., Clarke, R. C., & Nelson, J. (1987) · British Journal of Cancer · doi:10.1038/bjc.1987.49 · Cited by 86
Trial Watch: Toll-like receptor agonists in oncological indications
Aranda, F., Vacchelli, E., Obrist, F., Eggermont, A. M. M., Galon, J., Sautès‐Fridman, C., Cremer, I., ter Meulen, J. H., Zitvogel, L., Kroemer, G., et al. (2014) · OncoImmunology · doi:10.4161/onci.29179 · Cited by 85
Hope and Fear for Interferon: The Receptor-Centric Outlook on the Future of Interferon Therapy
Fuchs, S. Y. (2013) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2012.0117 · Cited by 84
Colombo, N., Peccatori, F. A., Paganin, C., Bini, S., Brandely, M., Mangioni, C., Mantovani, A., & Allavena, P. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910510109 · Cited by 79
Deonarain, R., Verma, A., Porter, A. C. G., Gewert, D. R., Platanias, L. C., & Fish, E. N. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2230460100 · Cited by 76
Type I Interferons Induce Apoptosis by Balancing cFLIP and Caspase-8 Independent of Death Ligands
Apelbaum, A., Yarden, G., Warszawski, S., Harari, D., & Schreiber, G. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.01430-12 · Cited by 74
Wagner, T. C., Velichko, S., Chesney, S. K., Biroc, S. L., Russell-Harde, D., Vogel, D., & Croze, E. (2004) · International Journal of Cancer · doi:10.1002/ijc.20236 · Cited by 73
Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses
Bhattacharya, S., HuangFu, W.-C., Dong, G., Qian, J., Baker, D. P., Karar, J., Koumenis, C., Diehl, J. A., & Fuchs, S. Y. (2012) · Oncogene · doi:10.1038/onc.2012.439 · Cited by 70
Bi, X., Hameed, M., Mirani, N. M., Pimenta, E. M., Anari, J. B., & Barnes, B. J. (2011) · Breast Cancer Research · doi:10.1186/bcr3053 · Cited by 68
Owczarek, C. M., Hwang, S. Y., Holland, K. A., Gulluyan, L. M., Tavaria, M. D., Weaver, B., Reich, N. C., Kola, I., & Hertzog, P. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.38.23865 · Cited by 66
Self-citationJeung, H., Moon, Y. W., Rha, S. Y., Yoo, N. C., Roh, J. K., Noh, S. H., Min, J.-S., Kim, B. S., & Chung, H. C. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm536 · Cited by 62
Crk adaptor proteins act as key signaling integrators for breast tumorigenesis
Fathers, K. E., Bell, E. S., Rajadurai, C. V., Cory, S. M., Zhao, H., Mourskaia, A., Zuo, D., Madore, J., Monast, A., Mes‐Masson, A., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3183 · Cited by 61
Toll-Like Receptors as Interferon-Regulated Genes and Their Role in Disease
Khoo, J. J., Forster, S. C., & Mansell, A. S. (2011) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2010.0095 · Cited by 61
Choi, E. A., Lei, H., Maron, D. J., Wilson, J. M., Barsoum, J., Fraker, D. L., El‐Deiry, W. S., & Spitz, F. R. (2003) · PubMed · Cited by 59
Bernardo, A. R., Cosgaya, J. M., Aranda, A., & Jimenez-Lara, A. M. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.5 · Cited by 59
Platanias, L. C., Shahab Uddin, M. S., Bruno, E., Korkmaz, M., Ahmad, S., Alsayed, Y. M., Berg, D. V. D., Druker, B. J., Wickrema, A., & Hoffman, R. (1999) · Experimental Hematology · doi:10.1016/s0301-472x(99)00060-0 · Cited by 59
Sun, Y., Yang, S., Sun, N., & Chen, J. (2014) · Pancreas · doi:10.1097/mpa.0000000000000074 · Cited by 56
Chronic myeloid leukemia cells resistant to interferon-α lack STAT1 expression
Landolfo, S., Guarini, A. R., Riera, L., Gariglio, M., Gribaudo, G., Cignetti, A., Cordone, I., Montefusco, E., Mandelli, F., & Foà, R. (2000) · The Hematology Journal · doi:10.1038/sj.thj.6200004 · Cited by 54
The Emerging Role of Immunosurveillance in Dictating Metastatic Spread in Breast Cancer
Slaney, C. Y., Rautela, J., & Parker, B. S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1642 · Cited by 54
Self-citationLacour, J., Lacour, F., Spira, A., Michelson, M., Petit, J., Delage, G., Sarrazin, D., Contesso, G., & Viguier, J. (1984) · BMJ · doi:10.1136/bmj.288.6417.589 · Cited by 50
Balkwill, F. R., Taylor‐Papadimitriou, J., Fantes, K. H., & Sebesteny, A. (1980) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(80)90237-6 · Cited by 48
Regulatory T cells increase in breast cancer and in stage IV breast cancer
Wang, Z.-K., Yang, B. Y., Liu, H., Hu, Y., Yang, J., Wu, L., Zhou, Z., & Jiao, S. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1158-4 · Cited by 47
Investigations of Interferon-Lambda for the Treatment of Cancer
Stiff, A. R., & Carson, W. E. (2015) · Journal of Innate Immunity · doi:10.1159/000370113 · Cited by 46
Hartman, L. L. R., Crawford, J. R., Makale, M., Milburn, M., Joshi, S., Salazar, A. Μ., Hasenauer, B., VandenBerg, S. R., MacDonald, T. J., & Durden, D. L. (2013) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000047 · Cited by 45
NK cells sense tumors, course of disease and treatments: Consequences for NK-based therapies
Fregni, G., Perier, A., Avril, M., & Caignard, A. (2012) · OncoImmunology · doi:10.4161/onci.1.1.18312 · Cited by 44
Quesada, J. R., Gutterman, J. U., & Hersh, E. M. (1982) · Journal of Interferon Research · doi:10.1089/jir.1982.2.593 · Cited by 44
Stein, B. L., & Tiu, R. V. (2013) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2012.0120 · Cited by 43
Laplanche, A., Alzieu, L., Delozier, T., Berlie, J., Veyret, C., Fargeot, P., Luboinski, M., & Lacour, J. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006498121628 · Cited by 40
Pasquali, S., & Mocellin, S. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710793176393 · Cited by 40
Boyer, C. M., Dawson, D. V., Neal, S. E., Winchell, L. F., Leslie, D. S., Ring, D. B., & Bast, R. C. (1989) · PubMed · Cited by 40
Anthony, S. M., Howard, M. E., Hailemichael, Y., Overwijk, W. W., & Schluns, K. S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120274 · Cited by 37
Gazziola, C., Cordani, N., Carta, S., Lorenzo, E., Colombatti, A., & Perris, R. (2005) · International Journal of Oncology · doi:10.3892/ijo.26.1.129 · Cited by 35
CHANGES IN CYTOKINE PRODUCTION OF BREAST CANCER PATIENTS TREATED WITH INTERFERONS
Barak, V., Kalickman, I., Nisman, B., Farbstein, H., Fridlender, Z. G., Baider, L., Kaplan, A., Stephanos, S., & Peretz, T. (1998) · Cytokine · doi:10.1006/cyto.1998.0378 · Cited by 34
Free interferon‐α/β receptors in the circulation of patients with adenocarcinoma
Ambrus, J. L., Dembinski, W., Ambrus, J. L., Sykes, D. E., Akhter, S., Kulaylat, M. N., Islam, A., & Chadha, K. C. (2003) · Cancer · doi:10.1002/cncr.11843 · Cited by 34
Samarajiwa, S., Mangan, N. E., Hardy, M. P., Najdovska, M., Dubach, D., Braniff, S.-J., Owczarek, C. M., & Hertzog, P. J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302388 · Cited by 33
Self-citationSeymour, L., & Bezwoda, W. R. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.339 · Cited by 32
Crk at the Quarter Century Mark: Perspectives in Signaling and Cancer
Kumar, S., Fajardo, J. E., Birge, R. B., & Sriram, G. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24749 · Cited by 30
How Much of a Good Thing? What Duration for Interferon Alfa-2b Adjuvant Therapy?
Tarhini, A. A., & Kirkwood, J. M. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.9975 · Cited by 30
Peginterferon α in the treatment of chronic hepatitis B
Tseng, T., Kao, J., & Chen, D. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.907784 · Cited by 29
Recchia, F., Sica, G., Filippis, S. D., Discepoli, S., Rea, S., TORCHIO, P., & Frati, L. (1995) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.1995.15.605 · Cited by 28
Buzzi, F., Brugia, M., Rossi, G., Giustini, L., Scoponi, C., & Sica, G. (1992) · PubMed · Cited by 27
Recchia (2009) · Oncology Reports · doi:10.3892/or_00000317 · Cited by 25
Watanabe, N., Narita, M., Yokoyama, A., Sekiguchi, A., Saito, A., Tochiki, N., Furukawa, T., Toba, K., Aizawa, Y., & Takahashi, M. (2006) · Cytotherapy · doi:10.1080/14653240600620200 · Cited by 24
Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma
DAUD, A. I., Soon, C. W. M., Dummer, R., et al. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.694421 · Cited by 23
Interferons and Their Antitumor Properties
Platanias, L. C. (2013) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2013.0019 · Cited by 23
Tamoxifen and interferon-beta for the treatment of metastatic breast cancer
Repetto, L., Giannessi, P. G., Campora, E., et al. (1996) · Breast Cancer Research and Treatment · doi:10.1007/bf01806190 · Cited by 22
Litterman, A. J., Dudek, A. Z., & Largaespada, D. A. (2013) · OncoImmunology · doi:10.4161/onci.26294 · Cited by 22
Chiesa, M. D., Passalacqua, R., Michiara, M., et al. (2007) · PubMed · Cited by 22
IFN-? limitin: a member of type I IFN with mild lympho-myelosuppression
Oritani, K., & Kanakura, Y. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00353.x · Cited by 21
Nicolini, A., Carpi, A., & Rossi, G. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.12.002 · Cited by 21
Safety of Toll-like receptor 9 agonists: a systematic review and meta-analysis
Qin, M., Li, Y., Xu, Y., & Wu, H. (2014) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2013.861481 · Cited by 20
Steroid receptor enhancement by natural interferon-β in advanced breast cancer
Sica, G., Iacopino, F., Lama, G., Amadori, D., Baroni, M., Sardo, F. L., Malacarne, P., Marchetti, P., Pellegrini, A., Zaniboni, A., et al. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)90378-s · Cited by 17
A phase I clinical tolerance study of polyadenylic-polyuridylic acid in cancer patients.
Jp, D., Caillé, P., Sancho Garnier, H., Jl, A., Michelson, M., Hovanessian, A. G., Jk, Y., & Lacour, F. (1985) · PubMed · Cited by 13
Beta-interferon, retinoids and tamoxifen combination in advanced breast cancer.
Recchia, F., Rea, S., Filippis, S. D., Rosselli, M., Corrao, G., Gulino, A., & Sica, G. (1998) · PubMed · Cited by 9
Lama, G., Angelucci, C., Recchia, F., & Sica, G. (1996) · Cancer Letters · doi:10.1016/0304-3835(95)04099-4 · Cited by 9
Natural interferon-beta and tamoxifen in hormone-resistant patients with advanced breast cancer.
Buzzi, E., Brugia, M., Trippa, F., Rossi, G., Trivisonne, R., Giustini, L., Pinaglia, D., Capparella, V., & Sica, G. (1995) · PubMed · Cited by 9
Tamoxifen and Alpha Interferon in Advanced Breast Cancer
Miglietta, L., Repetto, L., Gardin, G., AMOROSO, D., Giudici, S., Naso, C., Merlini, L., Queirolo, P., Campora, E., Pronzato, P., et al. (1991) · Journal of Chemotherapy · doi:10.1080/1120009x.1991.11739125 · Cited by 9
Effect of natural beta-interferon on estrogen receptor mRNA of breast cancer cells.
Sica, G., Angelucci, C., Iacopino, F., Lama, G., della Cuna, G. R., Serlupi‐Crescenzi, O., & Donini, S. (1992) · PubMed · Cited by 8
Martino, L. D., Demontis, B., Saccani Iotti, G., & Murenu, G. (1995) · PubMed · Cited by 5
Cited by
Dendritic cells in cancer immunology and immunotherapy
Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., & Sancho, D. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0210-z · Cited by 2,574
IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy
Ivashkiv, L. B. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0029-z · Cited by 1,358
Roles of IFN-γ in tumor progression and regression: A review
Jorgovanovic, D., Song, M., Wang, L., & Zhang, Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-00228-x · Cited by 1,234
Tumour-associated neutrophils in patients with cancer
Shaul, M. E., & Fridlender, Z. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0222-4 · Cited by 1,023
Phetsouphanh, C., Darley, D. R., Wilson, D. B., Howe, A., Munier, C. M. L., Patel, S. K., Juno, J. A., Burrell, L. M., Kent, S. J., Dore, G. J., et al. (2022) · Nature Immunology · doi:10.1038/s41590-021-01113-x · Cited by 1,015
Metadata
- Authors
- Parker, B. S., Rautela, J., & Hertzog, P. J.
- Venue
- Nature Reviews Cancer
- Published
- 2016-02-25
- Volume
- 16
- Issue
- 3
- Pages
- 131-144
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2275249553
- Cited by
- 907
- References
- 182
- FWCI
- 6.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.